Sugi Predict

Sugi Predict / Compounds / SCHEMBL3940936

SCHEMBL3940936

SCHEMBL3940936

CC1(O)CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.45
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ EPHX1 P07099 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ PREP P48147 1/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ CTSK P43235 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ USP30 Q70CQ3 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24095376 1.00 HPGD (0.45) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL24711544 1.00 HPGD (0.45) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL31460589 0.95 HPGD (0.48) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL31603608 0.95 HPGD (0.48) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL31460689 0.95 HPGD (0.48) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL25286793 0.90 USP2 (0.47) HPGDUSP2SMN1; SMN2EPHX1MAPT
SCHEMBL2218646 0.90 USP2 (0.47) HPGDUSP2SMN1; SMN2EPHX1MAPT
SCHEMBL5524618 0.87 HPGD (0.49) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL12683369 0.86 HPGD (0.47) HPGDUSP2SMN1; SMN2MEN1KMT2A
SCHEMBL14801055 0.86 USP2 (0.50) HPGDUSP2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025087282-A1 METHOD FOR PREPARING CHIRAL ALCOHOL COMPOUND 中国科学院上海有机化学研究所 2025-05-01 — — WO claimed
CN-119899090-A Preparation method of chiral alcohol compound 中国科学院上海有机化学研究所 2025-04-29 — — CN claimed
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 — — US disclosed
EP-3710458-B1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
EP-4631940-A1 COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF Betta Pharmaceuticals Co., Ltd. (CN) 2025-10-15 — — EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
US-12312370-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-05-27 — — US disclosed
WO-2025087282-A1 METHOD FOR PREPARING CHIRAL ALCOHOL COMPOUND 中国科学院上海有机化学研究所 2025-05-01 — — WO disclosed
CN-119899090-A Preparation method of chiral alcohol compound 中国科学院上海有机化学研究所 2025-04-29 — — CN disclosed
WO-2025081019-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2025-04-17 — — WO disclosed
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2018-06-07 — — US disclosed
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2018-06-07 — — US disclosed
EP-3233077-A1 DOPAMINE D2 RECEPTOR LIGANDS The Broad Institute Inc. (US) 2017-10-25 — — EP disclosed
WO-2016100940-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 — — WO disclosed
EP-2176250-B1 SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS CH (CH) 2011-10-26 — — EP disclosed
US-20100249093-A1 Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2010-09-30 — — US disclosed
US-20100249093-A1 Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2010-09-30 — — US disclosed
WO-2009016410-A2 CHEMICAL COMPOUNDS 831 ASTRAZENECA AB (SE) 2009-02-05 — — WO disclosed
WO-2009010299-A1 SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2009-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE KIF2C, KIF5B, KIF5C HPGD 4099/4885USP2 2094/4885SMN1; SMN2 218/4885
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, DRD3, ARRB1 HPGD 1231/4885USP2 2208/4885SMN1; SMN2 2087/4885
US-12312370-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 HPGD 2490/4885USP2 96/4885SMN1; SMN2 1377/4885
US-20100249093-A1 Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators MC4R, MC5R, MC3R HPGD 4119/4885USP2 3957/4885SMN1; SMN2 150/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 HPGD 2049/4885USP2 1115/4885SMN1; SMN2 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.